Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?

Do Low HDL Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01159613

Enrollment

Registered

2010-07-09

Start date

2008-04-30

Completion date

2009-01-31

Last updated

2010-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C Viral Infection

Keywords

SVR, Cholesterol level, fibrosis score, HDL

Brief summary

The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rate of sustained virologic response.

Detailed description

Lipoproteins are closely connected to the process of hepatitis C virus (HCV) infection. Metabolic syndrome predicts negative treatment outcome in HCV infection. Aim: to assess the association between lipids components of the metabolic syndrome and sustained viral response (SVR).

Interventions

OTHERResponders

Responders

OTHERNon Responders

Non Responders

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Chronic HCV genotype 1 naive patients

Exclusion criteria

* Co infection with HBV, HIV, HDV * Decompensated liver disease

Design outcomes

Primary

Measure	Time frame	Description
sustained viral response	72 weeks	achieving SVR

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026